Use of anti-CTLA-4 antibodies to treat adenoid cystic carcinoma
Anti-CTLA-4 antibodies like ONC-392, engineered for improved ADCC, provide an effective treatment for adenoid cystic carcinoma by targeting regulatory T cells, addressing the lack of therapeutic options for this cancer.
Patent Information
- Application Number
- JP2025515855
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-09-16
- Filing Date
- 2023-09-15
- Publication Date
- 2025-09-19
AI Technical Summary
There is a need for effective treatments for adenoid cystic carcinoma (ACC), a rare cancer with a high recurrence and metastasis rate, as current therapies are limited and no FDA-approved treatments exist, with existing anti-CTLA-4 antibodies showing suboptimal activity and adverse events.
The use of anti-CTLA-4 antibodies, such as ONC-392, which are engineered for enhanced antibody-dependent cellular cytotoxicity (ADCC) and improved half-life, administered as monotherapy or in combination with pembrolizumab, targeting regulatory T cells to overcome immune evasion in ACC.
ONC-392 demonstrates efficacy in treating recurrent and metastatic ACC by enhancing immune response, reducing tumor burden, and minimizing adverse events, offering a promising therapeutic option for this otherwise fatal cancer.
Smart Images
Figure 2025531229000001_ABST